Aurobindo Pharma arm gets U.S. FDA nod for generic of BMS’ cancer drug

Aurobindo Pharma’s Eugia Pharma has been approved the U.S. FDA to manufacture Dasatinib Tablets, a bioequivalent to Bristol-Myers Squibb’s Sprycel

Industry